Risks of hypomagnesaemia and increased risk of fracture with long-term PPI use
23rd April 2012
The UK Medicines and Healthcare products Regulatory Agency (MHRA) have alerted healthcare professionals of the possible risks of hypomagnesaemia and also increased fracture risk with long-term Proton Pump Inhibitor (PPI) use (generally >1year) in their latest Drug Safety Update publication.
- PCF4 print version now only £25!
- NICE evidence summary of oral ketamine for chronic pain
- First ever Global Atlas identifies unmet need for palliative care
- ACMD recommends reclassifying ketamine
- Phosphate enema new contra-indication
- Opioid antagonists therapeutic review
- NICE consultation on enhancing the BNF with other prescribing resources: an opportunity to lobby for the Palliative Care Formulary
- SIGN guidance on lung cancer updated
- Interim statement as LCP is phased out
- News about palliativedrugs.com publications in 2014